Two Sigma Investments, LP Dia Medica Therapeutics Inc. Transaction History

Two Sigma Investments, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.13 - $1.62 $2,676 - $3,837	-2,369 Reduced 16.32%	12,149 $19,000
Q3 2022 Nov 14, 2022	SELL	$1.2 - $2.07 $3,277 - $5,653	-2,731 Reduced 15.83%	14,518 $18,000
Q2 2022 Aug 15, 2022	SELL	$1.86 - $2.62 $61,043 - $85,985	-32,819 Reduced 65.55%	17,249 $35,000
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $207,906 - $352,261	-90,789 Reduced 64.45%	50,068 $125,000
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $228,359 - $309,583	66,577 Added 89.63%	140,857 $525,000
Q3 2021 Nov 15, 2021	BUY	$3.1 - $4.32 $230,268 - $320,889	74,280 New	74,280 $298,000

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.